Ganglioside (Cronassial) therapy in diabetic neuropathy.

Abstract

Cronassial, a combination of four different cerebral gangliosides, was evaluated in a six month double blind controlled study involving 25 patients with symptomatic diabetic neuropathy (12 receiving Cronassial, 13 receiving placebo). Clinically there was mild but definite improvement in the Cronassial patients. Small increases in sensory conduction velocities in Cronassial patients were also seen; their significance require further clarification. Measurements of neuronal responses du ischemia suggest that Cronassial may enhance anaerobic metabolism.

• Authors: S H Horowitz
• Journal: Advances in experimental medicine and biology (Adv Exp Med Biol) Vol. 174 Pg. 593-600 ( 1984) ISSN: 0065-2598 [Print] United States
• PMID: 6377852 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Gangliosides
• cronassial

Topics

• Adolescent
• Adult
• Aged
• Clinical Trials as Topic
• Diabetic Angiopathies (physiopathology)
• Diabetic Neuropathies (drug therapy, physiopathology)
• Electric Conductivity
• Evoked Potentials (drug effects)
• Female
• Gangliosides (therapeutic use)
• Humans
• Ischemia (physiopathology)
• Male
• Middle Aged
• Motor Neurons (physiology)
• Neurons, Afferent (physiology)
• Peripheral Nerves (drug effects, physiopathology)